| abstract |
The present invention relates to a dosage regimen of an S1P receptor modulator or agonist in the course of the treatment of patients suffering from an inflammatory or autoimmune disease or disorder, for example multiple sclerosis (MS). By administering a S1P receptor modulator or agonist according to the specific dosage regimen, it is possible to treat the patient efficiently while controlling, reducing, or eliminating possible adverse events, e.g. infection, recurrence of infection, or reactivation of latent infection, which may be associated with administration of such a compound. |